期刊文献+

比较紫杉醇联合奈达铂同期放化疗与奈达铂增敏放疗对食管癌的疗效 被引量:4

原文传递
导出
摘要 目的 观察比较紫杉醇联合奈达铂同期放化疗与奈达铂增敏放疗对食管癌的疗效及不良反应.方法 选择90例食管癌患者,按随机数字表法分为试验组(50例)和对照组(40例).试验组接受放疗联合紫杉醇及奈达铂化疗,对照组接受放疗联合奈达铂静脉滴注治疗,治疗4周后观察比较两组疗效和不良反应发生情况.结果 试验组总有效率和疾病控制率明显高于对照组[88.0%(44/50)比67.5%(27/40)、96.0%(48/50)比80.0%(32/40)],差异有统计学意义(P<0.05).试验组不良反应发生率为72.0%(36/50),对照组为65.0%(26/40),两组比较差异无统计学意义(P>0.05).两组骨髓抑制、放射性食管炎、恶心呕吐及肝肾功能损伤发生情况比较差异无统计学意义(P>0.05).结论 紫杉醇联合奈达铂同期放化疗治疗食管癌的疗效满意,近期疗效及疾病控制率明显优于奈达铂增敏放疗,两者不良反应相当,患者均可耐受.
出处 《中国医师进修杂志》 2014年第5期62-63,共2页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献8

二级参考文献61

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2黄镜,蔡锐刚,孟平均,张明娟,崔成旭,杨林,储大同,孙燕,王金万.紫杉醇联合顺铂治疗晚期食管鳞癌[J].中华肿瘤杂志,2004,26(12):753-755. 被引量:96
  • 3杨玲,李连弟,陈育德,D.M.Parkin.中国2000年及2005年恶性肿瘤发病死亡的估计与预测[J].中国卫生统计,2005,22(4):218-221. 被引量:336
  • 4吴剑,戴慧,翁欣然,林权冰,卢晓红.小剂量顺铂对中晚期食管癌放疗增敏作用的近期疗效观察[J].中国肿瘤临床,2006,33(13):768-770. 被引量:34
  • 5Whitney CW, Sause W, Bundy BN, et al. A randomized comparison of fluorouraeil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages Ⅱ B-ⅣA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Ontology Group and Southwest Oncology Group stndy [ J ] . J Clin Oncol, 1999, 17 [ 5 ] : 1339-1348.
  • 6Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: a randomized Radiation Therapy Oncology Group clinical trial [ J ] . N Engl J Med, 1999, 340 [ 15 ] : 1137-1143.
  • 7Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study [J].N Engl J Med, 1999,340 [15] :1144-1153.
  • 8Peters WA 3rd, Liu PY, Barrett RJ, et al. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunetive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase Ⅲ intergroup study [J]. J Clin Oncol, 2000, 18 [ 8 ] : 1606-1613.
  • 9Keys HM, Bundy BM, Stehman FB, et al. A comparison of weekly c, isplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage Ⅰ B cervical carcinoma: a randomized trial of the Gynecologic Oncology Group [ J ] . N Engl J ned, 1999, 340 [ 15 ] : 1154-1161.
  • 10Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine eervix: a systemic review and metaanalysis [ J ] . Lancet, 2001, 358 [ 9284 ] : 781-786.

共引文献57

同被引文献69

  • 1李阳.紫杉醇联合顺铂同步放疗治疗晚期食管癌疗效观察[J].黑龙江医学,2013,37(12):1194-1195. 被引量:3
  • 2Akutsu Y, Shuto K, Kono T, et al. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Hepatogastroenterology. 2012;59(119): 2095-2098.
  • 3Fencl P, Belohlavek O, Harustiak T, et al. The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma. Nucl Med Commun. 2012; 33(11) 1188-1194.
  • 4Ji Y, Zheng MF, Ye SG, et al. Agrocybe aegerita polysaccharide combined with chemotherapy improves tumor necrosis factor-a and interferon-~ levels in rat esophageal carcinoma. Dis Esophagus. 2013;26(8):859- 863.
  • 5Kobayashi N, Nakayama H, Osaka Y, et al. Tumor response after 10w-dose preoperative radiotherapy combined with chemotherapy for squamous cell esophageal carcinoma. Anticancer Res. 2013;33(3):1157-1161.
  • 6Choi N, Park SD, Lynch T, et al. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Int J Radiat Oncol Biol Phys. 2004;60(1):111-122.
  • 7Kim MK, Cho K J, Park SI, et al. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(1):115-121.
  • 8Akutsu Y, Kono T, Uesato M, et al. S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. Oncology 2013;84(5):305-310.
  • 9Koo DH, Park SI, Kim YH, et al. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol. 2012;69(3):655-663.
  • 10黄盛东,刘晓红,袁扬,龚德军.食管癌中p75^(NTR)阳性细胞池的变化与顺铂耐药机制的研究[J].中华实验外科杂志,2007,24(12):1560-1562. 被引量:9

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部